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Abstract 
 
RYAN MATTHEW PHILLIPS: Development of a Novel Assay of Protein Tyrosine 
Phosphatase Activity in Single Cells Using Capillary Electrophoresis 
(Under the direction of Nancy Allbritton, M.D., Ph.D.) 
 
  The inhalation of diesel exhaust particles has been linked to human diseases 
including airway inflammation, arrhythmias, heart attack, stroke, hypertension, and cancer.  
In vitro studies have implicated the inhibition of protein tyrosine phosphatases (PTPs) by 
diesel exhaust components as a contributor to the inflammatory processes underlying these 
conditions.  A more complete mechanistic understanding of this phenomenon could be 
achieved by observing the effects of diesel exhaust particle inhalation on the airways of 
exposed living human subjects.  While airway specimens can be obtained safely from these 
subjects by bronchial brushing, sample analysis is complicated by low total cell numbers, 
poor viability, and contamination with inflammatory cells and mucus.  We present a novel 
approach to the analysis of these challenging samples at the single-cell level that provides a 
direct measure of PTP activity without sacrificing information about intercellular 
heterogeneity commonly lost by analysis of bulk lysates. 
 A fluorescent phosphopeptide substrate of PTPs was synthesized and an analytical 
separation was developed to resolve and quantify phosphorylated and nonphosphorylated 
peptide, as well as potential degradation products, using capillary electrophoresis with laser-
induced fluorescence detection.  Peptide dephosphorylation was then used as a measure of 
PTP activity in a variety of model systems including recombinant PTPN1 and PTPN2, A431 
cell lysates, and single A431 cells.  The reporter was also used to characterize the inhibition 
iii 
 
of PTP activity in these systems by three toxic components of diesel exhaust particles: 
pervanadate, 1,2-naphthoquinone, and Zn
2+
. 
 The PTP reporter was then applied to common model systems of airway biology.  
PTP activity, as well as inhibition by the toxins listed above, was quantified in immortalized 
BEAS-2B bronchial epithelial cells as well as cultured primary human airway epithelial cells.  
PTP activity was then measured in single cells obtained directly from a living human subject 
via bronchial brushing.  The ability to analyze these small, heterogeneous samples of primary 
cells at the single-cell level demonstrates the power of this approach as new tool for the field 
of airway biology as well as for the broader study of PTP signaling. 
.  
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I.  Introduction 
Protein tyrosine phosphatases.  The protein tyrosine phosphatase (PTP) gene family 
consists of at least 100 members encoding enzymes capable of dephosphorylating proteins.
1
  
The classical PTPs are specific for phosphotyrosine-containing substrates, while the dual-
specificity phosphatases (DSPs) can act on phosphorylated tyrosine, serine, and threonine 
residues.  All catalytically active members of the PTP family share a characteristic 
phosphate-binding motif and act via a common mechanism.
2
  Briefly, a phosphotyrosine 
residue is brought into close proximity of the PTP catalytic cysteine by surrounding residues 
including an essential arginine.  Nucleophilic attack of the phosphotyrosine phosphate atom 
by the cysteine, P-O bond cleavage, and protonation of the tyrosine side-chain oxygen by a 
nearby PTP aspartate yields a phosphocysteine intermediate, which is subsequently 
converted to cysteine and free phosphate through hydrolysis of the unstable S-P bond by 
water.  While the key catalytic machinery is conserved across PTPs, variations in non-
catalytic regions of the phosphatase domain can lead to differing substrate specificity.  
Members of the PTP family participate in many facets of cell signaling and have been 
implicated in a variety of human diseases. 
 
PTP substrate recognition and specificity.  The classical PTPs can be divided into 
receptor (RPTP) and non-receptor (PTPN) types.  Although great structural variability exists 
between PTPs, the RPTPs comprise at minimum a phosphatase domain, a transmembrane 
region, and an extracellular region while the simplest PTPNs contain only a phosphatase 
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domain and adjacent unstructured regions.
3
  The higher-order structure of the PTP domain is 
highly conserved across PTPNs and RPTPs.
4
  Key features of the PTP domain include an 
absolutely conversed catalytic cysteine residue within the HCX5R “PTP signature motif”, a 
phosphotyrosine recognition loop containing a KNRY motif important for substrate 
recognition, a WPD loop containing an aspartic acid critical to the phosphatase mechanism, 
and a Q loop that stabilizes a catalytic water molecule.
5
  While the major features and overall 
fold of PTP domains is well conserved, the surface residues as well as several areas involved 
in substrate binding are highly variable to afford specificity of substrate recognition and 
interactions with scaffold and adapter proteins.  For instance, while the WPD loop is present 
across PTPs, specific residues within and adjacent to the loop determine the details of its 
structure and dynamics, which in turn affect substrate binding and catalysis.
6
  Variable 
residues critical to PTP substrate recognition also include two residues immediately N-
terminal to the tyrosine of the KNRY motif and residues within and adjacent to the secondary 
substrate-binding pocket found in some PTPs, including PTPN1.  Ultimately, the 
physiological substrate specificity of PTPs involves residues near the active site and more 
distant residues in the PTP domain that ensure proper substrate orientation, as well as the 
presence of additional protein-protein interaction domains and proper subcellular localization 
of PTPs.
7
 
 
Regulation of PTP activity.  While PTPs are critical to proper cell signaling, they 
must be tightly regulated to ensure signal integrity.  This regulation occurs through the 
control of PTP expression, the presence of necessary adaptors and scaffold proteins, spatial 
sequestration of PTPs, transient oxidative inhibition, and protection of phosphotyrosine 
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residues through protein binding.
8
  The latter three mechanisms of regulation have the 
greatest bearing on the work presented herein and therefore warrant further discussion. 
PTP activity can be regulated by targeting to specific regions of the cell, both to 
prevent undesirable dephosphorylation and to ensure proximity of PTPs to appropriate 
targets.
9
  The former is illustrated by PTP-1B and TC-PTP, which both possess hydrophobic 
C-terminal regions that target the enzymes to membranes including the endoplasmic 
reticulum.  While membrane-bound, these enzymes possess little to no enzymatic activity, 
but physiological cleavage of the targeting sequences results in soluble PTPs with 
significantly increased activity.  Targeting of active PTPs to specific cellular 
subcompartments has been observed, including cytoskeletal localization of PTPH1 by the 
Band 4.1 domain,
10
 as well as nuclear localization of PTPε by a removable N-terminal 
sequence
11
 and SHP-1 through a C-terminal sequence not found in the closely related SHP-2, 
which consequently does not localize to the nucleus.
12
  Because the physiological context of 
PTPs often involves spatial targeting within the cell, it is important to ensure that a reporter 
of PTP activity will be accessible to its enzyme of interest within the cell, and also underlines 
an important difference between measuring PTP activity in cell lysates and in intact cells. 
A second important mechanism of PTP regulation involves the transient inactivation 
of PTP catalytic activity through oxidation.  Catalysis by PTPs involves transfer of a 
phosphoryl group from a substrate tyrosine to the catalytic cysteine, in thiolate anion form 
(R-S
-
), of the PTP.
13
  This thiolate anion is highly susceptible to oxidation by reactive oxygen 
species generated secondary to growth factor receptor signaling and in response to cellular 
stresses such as ionizing radiation.  Oxidation of the thiolate anion to the sulfenic acid (R-
SOH) is reversible, while further oxidation to the sulphinic (R-SO2H) and sulphonic (R-
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SO3H) acids is irreversible.  To prevent permanent PTP inactivation, the sulfenic acid can 
react with the peptide backbone to form a sulfenamide bond (R-SN-R) or with reduced 
glutathione or another cysteine residue to form S-glutathionylated cysteine or a disulfide 
bond, respectively.  All of these products are less susceptible to further oxidation than 
sulfenic acid and permit regulation of signaling through reversible inactivation of PTPs.  
Proper regulation of PTPs through transient oxidation occurs in the complex redox 
environment of the intact cell, further supporting the value of studying PTP activity and 
inhibition in intact cells rather than lysates. 
A third mechanism of PTP regulation involves physical separation of the enzymes 
from potential substrates through protein domains that bind phosphotyrosine, primarily the 
phosphotyrosine-binding (PTB) and src-homology 2 (SH2) domains.
14
  Both of these 
domains are non-catalytic protein-protein interaction modules that recognize and bind 
phosphorylated tyrosine residues, albeit in different contexts.  The SH2 domain is found on a 
wide range of proteins including kinases, phosphatases, adaptors, transcription factors.  The 
SH2 domain recognizes substrates containing phosphotyrosine, and specificity is determined 
by interactions between substrate residues C-terminal to the phosphotyrosine and variable 
residues in the SH2 domain.
15
  PTB domains occur almost exclusively on proteins lacking 
kinase or phosphatase domains.  While substrate specificity is less well described for PTB 
domains, substrates recognized by PTB domains typically contain an NPX(Y/pY) consensus 
sequence.
16
  Interestingly, many PTB domains bind preferentially to nonphosphorylated 
tyrosine, and in some instances will also bind phosphoinositides.  Also, while SH2 domains 
typically recognize linear, unfolded peptide sequences, PTB domains more commonly 
recognize structured regions of proteins.
17
  While the differing contexts in which these 
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domains interact with phosphotyrosine contribute to the intricacy and complexity of cell 
signaling, both domains bind phosphotyrosine residues, simultaneously permitting signal 
transduction based on tyrosine phosphorylation status and preserving signals by physically 
preventing binding and subsequent dephosphorylation by PTPs.
18
 
 
PTPN1.  First reported by Tonks et al,
19
 PTPN1 (PTP-1B) is one of the most studied 
of the non-receptor PTPs, and plays critical roles in cell physiology and homeostasis. PTPN1 
modulates signal transduction through dephosphorylation of RTKs (e.g. βPDGFR,20 EGFR,21 
IR
22
), cytoplasmic kinases (e.g. JAK2,
23
 GSK-3β,24 Src25), transcription factors (e.g. 
STAT5,
26
 ESR1
27
) and adapter proteins (e.g. β-catenin,28 p62Dok29).  The broad signaling 
network of PTPN1 underlies its implication in disease processes including obesity, type II 
diabetes mellitus, cancer, and airway inflammation.
30-31
 
 While interest in PTPN1 activity and inhibition has fueled drug development efforts, 
few compounds have been tested in vivo.
32
  The PTPN1 inhibitor Trodusquemine (MSI-
1436) was shown to increase fat loss in murine models of obesity,
33
 leading to Phase I 
clinical trials in healthy and obese diabetic individuals.
34
  Ertiprotafib progressed through 
Phase II clinical trials as a potential treatment for Type II Diabetes Mellitus, but was 
abandoned due to undesirable off-target effects.
35
  Finally, studies in mice suggest that 
PTPN1 inhibition with 7-bromo-6-difluoromethylphosphonate 3-naphthalenenitrile may 
protect against progression and metastasis of some breast cancers,
36
 however this has not yet 
been demonstrated in humans and concerns exist about the complex nature of PTPN1 
signaling and the potentially far-reaching implications of its inhibition. 
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PTPN2.  PTPN2 (T-Cell Protein Tyrosine Phosphatase, TC-PTP) was originally 
described in T-cells, but is ubiquitously expressed in humans.
37
  Significant structural and 
functional similarities have been noted between PTPN2 and PTPN1.
38
  However, absence of 
these enzymes in mice result in different phenotypes,
39-40
 and structural differences have 
been identified as potential targets for specific inhibitors.
41
 
 Cancer has been a major focus of studies linking PTPN2 to human disease.  Absent or 
decreased PTPN2 is associated with tumorigenesis in certain forms of human T-cell acute 
lymphoblastic leukemia,
42
 and breast cancer,
43
 and inhibition of apoptosis in murine 
keratinocytes exposed to ultraviolet radiation.
44
  Conversely, deceased PTPN2 function 
results in  decreased viability and proliferation in murine B-cell lymphomas,
45
 suggesting 
that PTPN2 can both promote and inhibit carcinogenesis. 
 This duality of action extends beyond cancer.  Decreases in PTPN2 activity have been 
implicated in autoimmune disease due to insufficient regulation of T-cell receptor 
signaling,
46
 and specifically in ulcerative colitis and Crohn’s disease through disregulation of 
autophagy
47
 and inflammatory signaling
48
 in colonic epithelia.  However, partial inhibition of 
PTPN2 appears to prevent the development of insulin resistance in type 2 diabetes.
49
  The 
complicated implications of PTPN2 activity modulation may underlie the lack of clinical 
inhibitor development for this enzyme. 
 
Diesel exhaust particles and human health.  Cardiovascular disease is the leading 
cause of death in the US for both men and women, resulting in 34% of deaths in 2006.
50
  
While it is clear that genetic and dietary influences play a role in the development of 
cardiovascular disease, a less obvious contributor appears to be the very air we breathe, 
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particularly in areas with high levels of automobile and industrial pollution.  Processes like 
diesel fuel combustion generate fine and ultrafine particulate matter (PM) that deposits in the 
airways when inhaled.  Epidemiological studies have linked PM inhalation to increases in 
blood pressure,
51
 decreased cardiac autonomic control,
52
 and significantly increased risk of 
heart attack and stroke.
53
 
 While the details underlying these health effects has not been fully elucidated, PM 
exposure has been linked to increased extracellular signal-regulated kinase (ERK) dependent 
IL-8 secretion in airways,
54
 as well as increases in NF-κB and AP-1 activation and 
phosphorylation of p38 and JNK kinases,
55
 all indicative of an inflammatory response 
mechanism.  Recently, PM exposure has been shown to increase reactive oxygen species 
(ROS) in cells, resulting in activation EGFR
56
 and p38.
57
  A major contributor to the 
signaling disruptions associated with PM is intracellular PTP inhibition, which can be 
accomplished by several mechanisms as a result of the complex chemistry of PM.
58
 
 
Inhibition mechanisms of PTPs.  Physiological redox cycling of the phosphoryl-
accepting cysteine is key to phosphatase functionality and regulation, but non-physiological 
oxidation of PTPs has been noted as a mechanism of toxicity due to inhaled particulate 
matter (PM).  Transition metals in PM (e.g. iron, zinc, vanadium)
59
 can lead to ROS 
generation and oxidation of PTP active site cysteine residues.
60-62
  Oxidation of PTPs has 
also been identified as a potentially tumorigenic consequence of ionizing radiation through 
ROS generation and reversible S-nitrosylation.
63-64
  Exposure of cells to a 
60
Co radiation 
source generated reactive nitrogen species and caused reversible S-nitrosylation of active-site 
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cysteines.  Ultraviolet light has also been shown to oxidize these residues and inhibit PTPs 
secondary to reactive oxygen species generation. 
 A non-oxidative mechanism of PTP inhibition related to PM involves the covalent 
modification by quinones adsorbed to airborne particulates or formed intracellularly through 
metabolism of naphthalene.
65-66
  Specifically, exposure of PTPN1 to 1,2-naphthoquinone has 
been shown by mass spectrometry to result in covalent modification of cysteine and histidine 
residues.
67
  Non-oxidative inhibition can also result from binding of Zn
2+
 to the PTP active 
site.
68
  It should be noted that, while quinones and zinc can modify PTP through non-
oxidative mechanisms, these species are also implicated in cellular redox disruption through 
glutathione depletion.
69-70
 
 
Sources of heterogeneity in cell populations.  Investigations at the single cell level 
have shown a surprising level of heterogeneity, even within clonal populations.  In 
genomically unstable populations such as tumor cell lines, heterogeneity can result from the 
accumulation of isolated, stochastic genetic mutations and subsequent phenotypic alterations 
over time.
71
  However, non-genetic heterogeneity is also an important consideration, and can 
be subdivided into temporal and population heterogeneity.
72
 
 Temporal heterogeneity is the variation of some characteristic (e.g. protein 
expression) of a single cell over time.  The relatively low total number of biomolecules such 
as a specific mRNA or receptor, combined with the potential for high levels of amplification 
during translation or signal transduction can allow small, stochastic variations within a cell to 
yield significant phenotypic changes.
73-74
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 Population heterogeneity refers to temporally stable differences between clones.  
Computer modeling in conjunction with experimental validation suggests this phenomenon 
emerges from a combination of localized environmental fluctuations and subsequent cell-cell 
communication leading to adaptation such that while individual cells may differ, the net 
result of their signaling behavior maintains environmental homeostasis.
75
 
 While the variation among clonal populations of cells is a strong argument for 
pursuing techniques that measure signaling in single cells, the added complexity of tissue 
samples, whether from model organisms, human research subjects, or patients, provides 
further motivation.  Tissues are by definition a mixture of distinct cell types and bulk analysis 
of a mixed population averages multiple layers of heterogeneity into a single “typical” 
readout.  Two tissues of interest during this work were human bronchial brushings and tumor 
biopsies. 
 
Airway structure and bronchial brushings.  Healthy human airways serve a 
number of vital functions, including  air conduction, response to irritants and pathogens, and 
repair of damaged tissue.
76
  This variety of functions is accomplished by the interactions of a 
complex mixture of epithelia, fibroblasts, smooth muscle, neuroendocrine cells, lymphoid 
tissue, and extracellular matrix.
77
  While the complexity of this system is vitally important, it 
also complicates the analysis of airway biopsy samples, particularly when obtained by 
techniques such as bronchial brushing which, while less invasive than surgical biopsies, also 
provide small specimens with limited cell viability.
78
  Furthermore, this complexity is 
increased when studying disease processes of the airways due to the additional presence of 
acute or chronic inflammatory cells, excess mucous, and/or fibrosis.
79
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Measurement of enzyme activity with peptides.  Peptides allow investigation into 
the impact of protein primary (and sometimes secondary) structure on behavior.  While the 
interaction of a substrate peptide with an enzyme does not recapitulate potential higher order 
structure, peptides have been used to study a wide range of enzyme-catalyzed protein 
modifications (e.g. methylation,
80
 acetylation,
81
 ubiquitination,
82
 proteolysis
83
), though 
further discussion herein will focus on phosphorylation and dephosphorylation. 
 Perhaps the most straightforward application of peptides for measuring 
phosphorylation is the monitoring of transfer of radioactive phosphate from [γ-32P] ATP to a 
substrate peptide by a kinase.  This approach is widely used with enzyme-specific
84
 or 
generic peptide substrates (e.g. poly(Glu,Tyr) 4:1 copolymer)
85
 to measure kinase activity.  
While a powerful technique, relatively high limits of detection (10
-14
-10
-18
 mol) limit its 
utility in studying single cells.  Peptide substrate phosphorylation is also assessed via 
Western blot with anti-phosphotyrosine antibodies.
86
  The integration of SDS-PAGE with 
this approach affords separation and detection of multiple substrates.  Drawbacks to this 
technique include costly antibodies and relatively large sample size requirements.  Another 
powerful approach for evaluation of kinases using peptides is mass spectrometry.  Using this 
analytical technique, naturally occurring
87
 and synthetic peptides
88
 alike can be identified by 
molecular weight from complex samples including cell lysates
89
 and single cells
90
. 
Several approaches exist for development of peptide-based kinase sensors that exhibit 
a change in fluorescence in response to phosphorylation status.  A two-step assay has been 
demonstrated in which a rhodamine-conjugated kinase substrate is incubated with a kinase, 
then with an aminopeptidase.  Peptide cleavage by the aminopeptidase releases free 
11 
 
rhodamine 110 and results in a fluorescence increase, but serine-phosphorylation of the 
substrate prevents degradation and keeps the fluorophore in a conjugated, non-fluorescent 
state.
91
  A single-step alternative for kinase sensing involves development of environmentally 
sensitive sensors in which phosphorylation in the presence of an appropriate soluble 
phospho-motif binding domain results in a changes in solvation or quenching interactions 
and induce a fluorescence increase.
92
  Fluorogenic peptides have been used to measure 
phosphatase activity using tyrosine analogs that exhibit a fluorescence increase upon 
dephosphorylation
93
 as well as designs in which serine-dephosphorylation leads to peptide 
cyclization and fluorophore release.
94
 
 
Capillary electrophoresis.  Jorgenson and Lukacs first demonstrated that free-zone 
electrophoresis could be performed in thin glass capillaries to provide high resolution 
separations.
95
  Chief among the benefits described in this early work were the elimination of 
potentially adsorptive stabilizing media (gels, paper, etc.) and the elimination of thermal 
gradient formation as a major contributor to band broadening.  Since this initial report, 
capillary electrophoresis (CE) has evolved into a powerful analytical technique with a wide 
range of applications. 
 The simplest form of capillary electrophoresis, in which analytes migrate in free 
solution, is known as capillary zone electrophoresis (CZE).
96
  Analyte retention time in CZE 
is determined by the electrophoretic mobility (μep) of each analyte, as well as the velocity and 
direction of electroosmotic flow (EOF), a bulk fluid flow that occurs when a potential is 
applied to an electrolyte-filled capillary.  The μep for a species is proportional to the ratio of 
its charge and Stokes radius, while the EOF in an unmodified capillary will be directed 
12 
 
toward the negative electrode with a velocity dependent on electric field strength as well as 
buffer pH, ionic strength, and viscosity. 
 While CZE is a powerful separation technique, the inclusion of micelle-forming 
additives in the background electrolyte, known as micellar electrokinetic capillary 
chromatography (MEKC), can aid in difficult separations by providing a pseudostationary 
phase.  Under MEKC conditions, analytes migrate based on EOF and μep, but may also 
interact with micelles through electrostatic as well as hydrophibic interations.  The dynamic 
partitioning of analytes between free solution and large, relatively slow-moving micelles 
provides an additional parameter for distinguishing otherwise similar analytes. 
Analytes in CE can be detected by a variety of methods including absorbance, 
conductivity, mass spectrometry, and fluorescence.  Laser induced fluorescence (LIF) 
detection, in which fluorescent analytes are excited with a laser, can afford very high 
sensitivity on the order of 10
-21
 mol.
97
  LIF detection is limited to detection of fluorescent 
analytes, which may necessitate careful selection or modification of analytes, but also 
eliminates the potentially confounding detection of contaminants such as assay constituents 
and cell debris. 
 The high separation efficiencies, sensitivity, and selective detection have made CE-
LIF a powerful technique for single cell analysis.
98
  This technique has been used to quantify 
intracellular levels of endogenous neurotransmitters in single neurons
99
 and drug uptake in 
single leukemia cells.
100
  CE-LIF has also been used to study metabolism of sugars,
101
 
gangliosides,
102
 lipids,
103
 and peptides
104
 in single cells. 
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Analysis of fluorescent peptides using CE-LIF.  While fluorogenic peptides can 
provide real-time information about phosphorylation, but as only one species is fluorescent, 
phosphorylated and nonphosphorylated reporter cannot be quantified simultaneously.  This 
issue can be addressed using CE-LIF, which has been demonstrated for purified peptides, in 
vitro assays, cellular lysates, and single cells.  Because fluorescence does not rely on 
phosphorylation status, both species can be quantified simultaneously.  Peptides containing 
tryptophan or phenylalanine can be detected (ex: ~270 nm, em: 305 nm) without 
derivitization,
105
 however this method lends itself to confounding from other biological 
components containing these residues.  Derivitization of analytes with fluorophores permits 
detection at wavelengths unlikely to overlap significantly with native fluorescence.  A wide 
range of reactive fluorophores are available for functionalization of the amines, hydroxyls, 
carboxylic acids, and sulfhydryls present on peptides and proteins (bioconjugate techniques), 
and many have been used in conjuction with CE-LIF either prior to electrophoresis (off-
column) or within the capillary (on-column).
105
  For analysis of synthetic peptides, 
fluorophores can be readily conjugated to the N-terminus or to reactive side chains such as 
lysine using standard SPPS.  
 
Solid Phase Peptide Synthesis.  Solid-phase peptide synthesis (SPPS) using N-α-
fluorenylmethyloxycarbonyl (Fmoc) chemistry is a convenient, efficient, and widely utilized 
alternative to conventional organic synthesis.  The overall workflow of Fmoc-based SPPS 
involves immobilization of the C-terminal amino acid to a resin bead followed by sequential 
deprotection of the N-terminus and peptide elongation through coupling of a soluble 
14 
 
carboxylic acid.  The completed peptide is then cleaved from the resin for purification and 
characterization.
106
 
Polystyrene resin beads serving as solid support for synthesis afford rapid reagent 
exchange and dramatically simplify multi-step syntheses.  Beads can be functionalized with a 
variety of linkers to yield products with C-terminal moieties including amides, carboxylic 
acids, and sulfhydryl groups.  Linker identity also dictates the conditions under which the 
peptide is removed from the resin.  The acid-labile trialkoxybenzhydrylamine (Rink amide) 
linker was used for synthesis of the peptide amides TS13 and pTS13, while peptide acid 
fragments were synthesized using the highly acid-labile 2-chlorotrityl chloride linker. 
 Peptides often contain amines, carboxylic acids, hydroxyls, or sulfhydryl moieties 
that require chemical modification, in the form of orthogonal protecting groups, to avoid 
undesirable reactivity during synthesis.  The use of N-α-fmoc protected amino acids prevents 
off-resin amide bond formation during peptide elongation.  Groups such as tert-butyl (tBu), 
O-tert-butyl (OtBu), and tert-butoxycarbonyl (BOC) are commonly used to protect 
carboxylic acids, hydroxyls, and amines.  These groups are removed during cleavage from 
the resin and thus are inappropriate for on-resin side-chain modification.  However, 
protecting groups such as methyltrityl (Mtt) can be removed under otherwise minimally 
disruptive conditions and thus facilitate on-resin side-chain modifications. 
While many strategies for peptide bond formation exist, one of the most common 
approaches involves benzotriazolyl (OBt) ester formation.  Pre-incubation of an N-α-Fmoc 
protected amino acid with 1-hydroxybenzotriazole (HOBt) and an activator such as 2-(6-
chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) or 
diisopropylcarbodiimide (DIC) results in the formation of an OBt ester at the α-carbonyl.  
15 
 
This ester is susceptible to nucleophilic attack by the N-terminal free amino of the resin-
bound peptide, leading to peptide bond formation. 
 
Origins of the TS13 and pTS13 sequences.  The observation that tyrosine kinases 
preferentially phosphorylate sites with nearby acidic residues
107
 led to investigation of 
numerous proteins as potential EGFR substrates, including human erythrocyte Band 3 
Protein.
108
  The acidic N-terminus of this protein  served as the basis for the highest affinity 
EGFR peptide substrate known (Km = 34 μM).
109-110
  This peptide in turn was modified with 
an N-terminal fluorescein to produce TS13 and its phosphotyrosine-containing analogue 
pTS13. 
 
A431 cells.  The A431 cell line was cultivated from a human epidermoid carcinoma 
specimen by Giard and colleagues.
111
  These cells produce large quantities of wild-type 
EGFR,
112
 approximately 2.6 x 10
6
 receptors/cell,
113
 due to genetic amplification through 
chromosomal translocations.
114
  These cells have been essential in the study of PTP activity 
and inhibition.  Lee et al observed that treatment of A431 cells with EGF results in reversible 
PTP1B inhibition linked to a transient increase in intracellular H2O2.
115
  The mechanism of 
this inhibition, PTP sulfenylation, was subsequently described in A431 lysates
116
 and later in 
living A431 cells.
117
  These cells have also been used to study the importance of PTPs in cell 
adhesion
118
 and as transducers between GPCRs and RTKs.
119
 
 
BEAS-2B cells.  The BEAS-2B cell line was established and reported by Reddel and 
colleagues in 1988.
120
  Normal human bronchial epithelial cells were obtained by autopsy 
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and exposed to Ad12-SV40 virus, resulting in immortalized, nontumorigenic bronchial 
epithelia that were continuously propagated in culture for over one year.  While BEAS-2B 
cells are non-ciliated,
121
 they bear similarities to primary epithelia cultured as a monolayer in 
terms of antioxidative capacity,
122
 inflammatory response,
123
 and matrix attachment.
124
  
These similarities have facilitated many studies of inflammatory signaling due to chronic 
disease as well as environmental exposures.
125-129
 
 
Primary human airway epithelial cells (hAECs).  In addition to immortalized cell 
lines, primary hAECs obtained from necropsy or living human subjects can be cultured used 
for airway biology research.  While monolayers of these cultured cells are widely used to 
study airway physiology and disease, this approach does not fully recapitulate the conditions 
of human airways, in which cells exist at an air-liquid interface (ALI).  While ALI cell 
culture techniques can be used to reproduce the native environment of primary airway cells, 
the rapid changes in transepithelial electrical resistance, differentiation potential, and 
heterogeneity that occur when these cells are grown in traditional culture
130
 underline the 
value of approaches that allow analysis of signaling behavior as quickly as possible after 
tissue procurement without the need for cell culture. 
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II.  Measurement of Protein Tyrosine Phosphatase Activity in Single Cells by Capillary 
Electrophoresis 
 
Overview 
A fluorescent peptide substrate was used to measure dephosphorylation by protein 
tyrosine phosphatases (PTP) in cell lysates, and single cells and to investigate the effect of 
environmental toxins on PTP activity in these systems.  Dephosphorylation of the substrate 
by PTPN1 and PTPN2 obeyed Michaelis-Menten kinetics, with KM values of 770 ± 250 nM 
and 290 ± 54 nM, respectively.  Dose-response curves and IC50 values were determined for 
the inhibition of these two enzymes by the environmental toxins Zn
2+
 and 1,2-
naphthoquinone, as well as pervanadate. In A431 cell lysates, the reporter was a poor 
substrate for peptidases (degradation rate of 100 ± 8.2 fmol min
-1
 mg
-1
) but an excellent 
substrate for phosphatases (dephosphorylation rate of 1.4 ± 0.3 nmol min
-1
 mg
-1
). Zn
2+
, 1,2-
naphthoquinone and pervanadate inhibited dephosphorylation of the reporter in cell lysates 
with IC50 values of 470 nM, 35 μM, and 100 nM, respectively.  Dephosphorylation of the 
reporter following loading into living single cells occurred at rates of at least 2 pmol min
-1
 
mg
-1
.  When single cells were exposed to 1,2-naphthoquinone (50 μM), Zn2+ (100 μM), and 
pervanadate (1 mM), dephosphorylation was inhibited with median values and first and third 
quartile values of 41 (Q1 = 0%, Q3 = 96%), 50  (Q1 = 46%, Q3 = 74%), and 53% (Q1 = 36%, 
Q3 = 77%) , respectively, demonstrating both the impact of these toxic exposures on cell 
signaling and the heterogeneity of response between cells.  This approach will provide a 
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valuable tool for the study of PTP dynamics, particularly in small, heterogeneous populations 
such as human biopsy specimens.  
  
Introduction 
The human genome encodes 107 protein tyrosine phosphatases (PTPs),
1
 enzymes 
containing a catalytic cysteine residue capable of removing phosphoryl moieties from 
tyrosine residues on proteins.  This enzyme family plays a critical role in maintaining proper 
cell signaling through its opposition of protein tyrosine kinases and dysregulation of these 
key enzymes is associated with many diseases, including type I diabetes mellitus, cancer, and 
rheumatoid arthritis.
2
  PTP inhibition is also linked to the toxicity associated with inhalation 
of diesel exhaust particles (DEP), an important component of air pollution.
3
  Combustion of 
diesel fuel by vehicles and industrial equipment produces fine particulate matter (diameter < 
2.5 μm) containing a mixture that includes elemental carbon, polyaromatic hydrocarbons, 
and metals.
4
  The deposition of these particles in small airways and alveoli is associated with 
numerous human health hazards including heart attacks, arrhythmias, chronic obstructive 
pulmonary disease (COPD), and asthma.
5
  In vitro studies have linked DEP components to 
reactive oxygen species production
6
  as well as direct inhibition of PTPs.
7
 
Although studies on purified PTPs, cell lysates, and fixed tissue samples have 
provided valuable insight into the role of diesel exhaust particles in human disease, analysis 
of ex vivo samples acquired from human subjects remains challenging.  Bronchial brushing 
(BB) is a well-established method of obtaining airway cells for analysis by dislodging them 
with a brush in conjunction with fiberoptic bronchoscopy.
8
  Although BB samples are a 
valuable source of primary airway cells for research, the sample size is typically very limited 
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(0.8-3.6 x 10
4
 cells).
9
  The small sample size is further complicated by the specimen 
heterogeneity which in addition to the intact airway epithelia contains mucus, stromal tissue, 
and the remnants of cells killed during dislodging.  To date, direct analysis of these 
specimens has focused on genetic techniques including fluorescence in situ hybridization 
(FISH),
10
 RNA microarrays,
11
 and polymerase chain reaction (PCR).
12
  Although these 
approaches provide valuable information, new analytical tools for these BB specimens are 
required to provide additional information about the biochemistry of human airway cells.  
The direct measurement of cell processes by chemical cytometry has the potential to 
provide unique advantages in the study of BB specimens.  Although a wide range of 
chemical cytometry approaches exist,
13
 the measurement of PTP activity in airway specimens 
must be compatible with very small numbers of heterogeneous primary cells, and single-cell 
CE-LIF is a promising approach to address this challenge.  Sample heterogeneity is readily 
addressed by the selection and analysis of individual cells, while the high separation 
efficiency and detection limits approaching 10
-21
 mol
14
 have made it possible to study many 
aspects of single cells, including protein and lipid  kinase activity, proteolysis, nitric oxide 
release, and response to oxidative stress.
14-15
  Because PTPs are part of a complicated 
signaling network, the ability to multiplex measurement of several enzymes is very attractive, 
and CE has been used for monochromatic detection of up to 20 analytes simultaneously
16
 and 
multicolor systems have also been described.
17
 
Herein we demonstrate the utility of single-cell capillary electrophoresis for the 
measurement of PTP activity in single intact cells, a technology well-suited for analysis of 
small heterogeneous samples such as that from a BB.  We developed and validated a 
fluorescent peptide reporter of PTP activity and measured the kinetics of dephosphorylation 
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by two common model phosphatases.  Additionally, we observed inhibition of these 
phosphatases by three toxins known to be present in diesel exhaust and then generated dose-
response curves for the environmental toxins. A separation method for the peptide and all 
possible fluorescent cleavage products was developed so that peptide cleavage in cell lysates 
and intact cells could be quantified.  The lifetime of the peptide, dephosphorylation rate and 
influence of environmental toxins was assessed in A431 cell lysates.  Finally, the peptide 
lifetime and the dephosphorylation rate in single A431 cells were quantified in the presence 
and absence of environmental toxins.  This work was published in Analytical Chemistry.
18
 
 
Experimental Section 
Materials. N-α-(9-fluorenylmethyloxycarbonyl) protected amino acids, 2-(6-Chloro-
1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), N-
hydroxybenzotriazole (HOBt), 1,3-diisopropylcarbodiimide (DIC), and  TentaGel Rink 
(TGR) resin were obtained from EMD Novabiochem.   6-Carboxyfluorescein (6-FAM) was 
obtained from Anaspec and recombinant phosphatases were purchased from Millipore.  
Bovine serum albumin (BSA) was from Calbiochem, Dulbecco’s Modified Eagle’s Medium 
(DMEM) from Cellgro, penicillin/streptomycin (PS) and 0.25% Trypsin from Gibco, and 
fetal bovine serum (FBS) from Atlanta Biologicals.  Sylgard 184 polydimethylsiloxane 
(PDMS) was purchased from Dow Corning.  All other chemicals were purchased from either 
Sigma or Fisher. 
Peptide Synthesis and Characterization.  The full-length substrate peptide, termed 
“pTS13” when phosphorylated and “TS13” when nonphosphorylated, was synthesized using 
standard solid-phase peptide synthesis techniques on TGR resin, while peptide acid 
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fragments were synthesized on 2-chlorotritylchloride resin, both using an automated peptide 
synthesizer (PS3, Protein Technologies, Tuscon, AZ).  Peptide synthesis was accomplished 
by coupling 5 equivalents (eq) of N-α-Fmoc protected amino acid in N,N-
dimethylformamide (DMF) with HCTU (5 eq) and N-methylmorpholine (10 eq) for 20 min.  
Unreacted amines were then acetylated using 1:1 acetic anhydride in DMF.   N-terminal 
deprotection was achieved using two 15 min incubations with 30% (v/v) piperidine in DMF.  
Coupling of 6-carboxyfluorescein (3 eq) to the peptide N-terminus was performed manually 
using DIC (3 eq) and HOBt (3 eq) in DMF for 24 h, followed by two 15 min incubations 
with 30% (v/v) piperidine in DMF.  Cleavage from TGR resin and side-chain deprotection 
was accomplished by incubating in 95% TFA, 2.5% triisopropylsilane, 2.5% water for 3 h at 
room temperature.  TFA was evaporated under a stream of N2 gas, followed by peptide 
precipitation with ice-cold diethyl ether.  Peptides were allowed to dry overnight then 
dissolved in water for purification by C18 reversed-phase HPLC, followed by lyophilization 
and storage at -20 ⁰C.  Peptide molecular weight was confirmed by matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) using an AB4800 
(Applied Biosystems, Carlsbad, CA) and α-cyano-4-hydroxycinnamic acid (CHCA) matrix. 
Capillary Electrophoresis. Separation of the peptide reporter based on 
phosphorylation status was performed using 140 mM borate, 150 mM SDS, 50 mM NaCl in 
a bare fused-silica capillary [30 µm inner diameter, 350 µm outer diameter, (Polymicro 
Technologies, Phoenix, AZ)] .  Separations were performed on either a ProteomeLab PA800 
(Beckman Coulter, Fullerton, CA) with a 30 cm long capillary, or on a customized system 
with a 38 cm long capillary.  Capillaries were conditioned before use with successive rinses 
of 0.1 M NaOH (12 h), water (1 h), 0.1 M HCl (6 h), and water (12 h).  Laser-induced 
32 
 
fluorescence (excitation: 488 nm, detection: 532 nm) was used for detection of fluorescent 
peptides.  On the commercial system, samples were loaded into the capillary by applying 
positive pressure (0.5 psi for 5 s) to the capillary inlet followed by separation at 8 kV (267 
V/cm) with a negative outlet.  On the customized system, electrokinetic sample loading (79 
V/cm for 5 s, negative outlet) was followed by separation at 10 kV (263 V/cm).  Data were 
acquired with software written in Labview (National Instruments, Austin, TX) or with 32 
Karat software (Beckman Coulter, Brea, CA) and analyzed using Matlab (The Mathworks, 
Natick, MA) and Origin (OriginLab, Northampton, MA) software. 
Recombinant Phosphatase Activity Assay.  Dephosphorylation of peptide by 
recombinant human PTPN1 and PTPN2 was observed with and without the PTP inhibitors 
pervanadate, 1,2-naphthoquinone, and zinc.  The PTPN1 used was a human, N-terminal 
GST-tagged construct (residues 1-321) while the PTPN2 was a human construct (residues 1-
341), both expressed in E. coli.  For some reactions, PTP was incubated with the 
environmental toxins pervanadate, 1,2-naphthoquinone, or zinc pyrithione for 10 min at 21 
°C prior to addition of pTS13.  PTP was diluted (11.1 pg/ μL for PTPN1, 2.8 pg/ μL for 
PTPN2) in 90 μL of reaction buffer (60 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 150 mM sodium chloride, 0.17 mM dithiothreitol, 0.83 (v/v)% glycerol, 0.017 
(w/v) % BSA, 0.002% Brij-35, pH 7.2), followed by addition of pTS13 in water to final 
peptide concentrations of 780 nM or 280 nM for reactions with PTPN1 or PTPN2, 
respectively, and the reactions were allowed to proceed at 21 °C for 10 min.  Reactions were 
terminated by addition of an equal volume of 200 μM HCl and samples were stored at -20 °C 
prior to analysis.  CE of each sample was performed and the percent dephosphorylated 
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peptide was calculated as the area of the dephosphorylated peptide peak divided by the total 
area of all peptide peaks on the electropherogram. 
Determination of Kinetic Constants.  The Michaelis constant, KM, and maximum 
reaction velocity, Vmax, were determined for the interaction of recombinant PTPN1 and 
PTPN2 with pTS13 by measuring initial reaction rates over a range of pTS13 concentrations.  
Recombinant PTPN1 (3.3-6.7 pg/ μL) or PTPN2 (0.67-1.7 pg/ μL) in reaction buffer was 
incubated with pTS13 (110-1390 nM) as described above.  The amount of product formed 
was measured by CE at multiple time points for each substrate concentration and initial rates 
were plotted versus substrate concentration.  Nonlinear regression of the data using the 
Michaelis-Menten equation was performed using Origin software and kinetic constants were 
calculated. 
Cell Culture.  A431 cells, a human epidermoid carcinoma cell line expressing high 
levels of EGFR,
19
 were grown in a humidified atmosphere at 37 °C and 5% CO2 .  Cells were 
cultured in 75 cm
2
 tissue culture flasks in DMEM (10 (v/v) % FBS, 1 (v/v) % P/S) and were 
passaged at 60-80% confluency using 0.25% trypsin. 
Cell lysate experiments.  A431 cells from two 75 cm
2
 culture flasks were trypsinized 
for 5 min, diluted in DMEM, centrifuged 2 min at 800 x g, and then washed twice with PBS 
and pelleted.  After removal of the supernatant, the pellet was resuspended in lysis buffer (20 
mM HEPES, 1% Triton X-100, 10% Glycerol, 200mM NaCl, 5 mM β-glycerophosphate) 
with 1 (v/v) % Sigma Protease Inhibitor Cocktail.  Lysate was mixed end-over-end for 20 
min, followed by centrifugation at 15000x g for 40 min.  The supernatant was transferred to a 
fresh 1.5 mL tube and protein concentration was measured as previously reported
20
.  Lysates 
were then diluted to 10 mg/mL total protein and stored at -20 ⁰C for up to 1 month. 
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 For phosphatase assays, cell lysates were diluted to 111 ng/μL total protein in 90 μL 
of reaction buffer (described above) with or without environmental toxins.  After 10 min of 
pre-incubation, pTS13 in water was added to a final concentration of 280 nM and the 
reaction was allowed to proceed for 90 s.  Reactions were stopped by addition of an equal 
volume of 200 μM HCl.  Samples were analyzed by CE to establish percent 
dephosphorylation and to determine if fluorescent peaks in addition to the intact 
phosphorylated and nonphosphorylated peptide appeared on the electropherograms.  
Dephosphorylation rates were reported as nmol peptide per minute per mg total cell protein 
(nmol min
-1
 mg
-1
).  For inhibition experiments, dose response curves were generated over a 
range of inhibitor concentrations and IC50 values were interpolated by regression of the 
linear portion of the semi-log plot of percent inhibition versus log10 of inhibitor 
concentration.  
Single Cell Phosphatase Measurement.  A431 cells were grown in DMEM on cell 
chambers comprising a round 25 mm diameter No. 1 glass coverslip bonded to a silicone O-
ring (18 mm internal diameter) with PDMS.  Pretreatment of cells, if any, was performed by 
removing media from a cell chamber, rinsing twice with 37 ⁰C serum-free DMEM and then 
adding the appropriate inhibitor dissolved in serum-free DMEM and incubating at 37 ⁰C for 
10-20 min.  After pretreatment, a cell chamber was placed on the microscope stage of the 
customized single-cell CE system,
21
 a cell was visualized and microinjected with a mixture 
of peptide reporter and internal standard using a Transjector 5246 microinjection system 
(Eppendorf AG, Hamburg, Germany).  The cell chamber temperature was maintained at 37 
⁰C using a constant flow of warmed extracellular buffer (ECB; 10 mM HEPES, 135 mM 
NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, pH 7.4) during microinjection, reporter 
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incubation, and cell lysis.  At 60 s post-microinjection, the cell was lysed with a 532 nm 
ND:YAG pulsed laser
22
 and electrokinetically injected into the capillary by applying a 
negative potential to the capillary outlet reservoir (5 s at 79 V/cm).  The capillary inlet was 
then repositioned into a reservoir of electrophoretic buffer (140 mM borate, 150 mM SDS, 50 
mM NaCl, pH 7.0), electrophoresis was performed (263 V/cm), and data was analyzed using 
Matlab and Origin.  Data from untreated and inhibitor treated cells was compared using 
bootstrapping
23
 and p-values were reported. 
Statistical Analysis.  The distribution of the difference between the mean %pTS13 
remaining in each treatment group and the control group was calculated using bootstrapping.  
10,000 bootstrap replicates were sampled (with replacement) from each group and the means 
of each bootstrap replicate were calculated.  The distribution of the mean differences was 
estimated by the distribution of the differences between the appropriate pairs of bootstrap 
replicates.  95% confidence intervals for each difference were estimated using the bias-
corrected and accelerated (BCa) method.  The p-value for testing the null hypothesis of no 
difference in mean between each treatment group and the control group was estimated by 
dividing the number of bootstrap differences 0 or less by the total number of bootstrap 
replicates (i.e. 10,000). 
 
Results and Discussion 
Peptide Selection and Separation.  In order to measure PTP activity in single cells, 
a phosphotyrosine-containing peptide reporter sequence (Glu-Glu-Leu-Glu-Asp-Asp-pTyr-
Glu-Asp-Asp-Nle-Glu-Glu-amide, where Nle is norleucine) was chosen.  The sequence was 
adapted from a peptide substrate of epidermal growth factor receptor (EGFR),
24
 a receptor 
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tyrosine kinase opposed by phosphatases including PTPN1, PTPN2, SHP-1, and Cdc25A.
25-
26
  6-FAM was conjugated to the N-terminus to permit fluorescence detection.  Since 
incubation of peptides in cells or cell lysates can result in their metabolism by peptidases 
with cleavage at any peptide bond, the ability to electrophoretically separate pTS13, TS13 
and their fluorescent fragments which are similar in charge/mass was critical for use of 
pTS13 as a reporter in cell lysates and single cells. Moreover it was critical that the sample 
matrix used for the separation be that of a physiologic buffer since the ultimate goal of this 
work was measurement of single-cell, reporter dephosphorylation during toxin exposure. 
Initial methods development focused on the separation of pTS13 and TS13. A survey 
of separation buffers previously reported for peptides and highly negative analytes comprised 
borate with and without sodium dodecyl sulfate (SDS) or cetyltrimethlammonium bromide 
(CTAB), sodium citrate, sodium phosphate with SDS, tris(hydroxymethyl)aminomethane 
(Tris), and 1,1-bis(hydroxymethyl)ethyl)glycine (Tricine).
27
  The best resolution observed 
during this screening was 1.3 ± 0.1 for 140 mM borate, 70 mM SDS, pH 7.5.  This 
concentration of SDS is well above its critical micelle concentration (7.9-8.3 mM)
28
 and thus 
the mode of separation was expected to be micellar electrokinetic capillary chromatography, 
modified by borate complexation.  For both lysate and single-cell analyses, the sample matrix 
was not the electrophoretic buffer but a high-salt biocompatible buffer.  When pTS13 and 
TS13 were loaded into the capillary using a high-salt, neutral-pH buffer (ECB) as the sample 
matrix, the peaks were no longer resolved (Figure 2.1a). The loss in separation capacity was 
most likely due to destacking of the analytes in the high ionic strength sample matrix.  To 
minimize destacking when using high salt samples, 50 mM sodium chloride was added to the 
electrophoretic buffer to more closely match the ionic strength of the sample matrix i.e. 
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physiologic buffer, and SDS concentration was increased to 150 mM to increase micellar 
sweeping effects.  Although the added salt minimized destacking, it resulted in a greatly 
increased current flow through the capillary necessitating electrophoretic separations at very 
low field strengths (≤ 160 V/cm) and consequent long separation times (1680 ± 54 s for 
TS13, 1760 ± 63 s for pTS13). For this reason, all subsequent separations were performed in 
a 30 μM ID capillary to maintain acceptable field strengths (260 V/cm) at low currents and 
shorter separation times (1170 ± 22 s for TS13, 1230 ± 26 s for pTS13).  These conditions 
yielded separation of pTS13 and TS13 with a resolution of 3.4 ± 0.1, and efficiencies of 7.3 ± 
0.6 x 10
4
 (TS13) and 6.7 ± 0.5  x 10
4
 (pTS13) theoretical plates (Figure 2.1b). Importantly, 
the ratio of the peak areas of pTS13 and TS13 to that of the total peptide was highly 
reproducible with an RSD of 0.032 and 0.023, respectively.  Although these efficiencies are 
lower than for many peptide separations by CE, the highly negative analytes and high-salt 
sample matrix make this a challenging separation. Most important, the resolution was 
sufficient for the intended biological  
application.  The limit of detection for pTS13, defined as the smallest amount of analyte 
detectable with a signal-to-noise ratio greater than 3, was determined to be 4.4 x 10
-20
 mol. 
The phospho- and nonphospho-peptides migrated 60 s apart; however, this spacing 
was not sufficient to consistently identify single peaks given the variability in the migration 
time especially in the presence of potentially biofouling constituents such as protein or cell 
debris. For this reason, 6-FAM was used as an internal standard for all biologic samples.  
This dye is detectable by LIF and migrates near TS13 and pTS13.  The 12 possible 
fluorescent fragments generated by removal of C-terminal residues from TS13 were 
synthesized.  Separation of all analytes simultaneously (Figure 2.1c) demonstrated that no 
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fragments co-migrated with 6-FAM, pTS13, or TS13, and thus any degradation of the 
reporter within the biologic sample will produce additional CE peaks. 
Kinetics of in vitro Dephosphorylation.  The human enzymes PTPN1 (PTP-1B) and 
PTPN2 (TC-PTP) favor substrates with acidic side-chains proximal to the phosphotyrosine 
residue, and are implicated in airway inflammation.
29-31
  To determine if phosphatase activity 
could be measured using pTS13, the reporter at varying concentrations was incubated with 
recombinant PTPN1 and PTPN2.  Product formation was quantified by CE and the percent 
dephosphorylated peptide was calculated as the ratio of the integrated area of the TS13 peak 
to the combined area of the pTS13 and TS13 peaks.  The Michaelis constant (KM), maximal 
reaction velocity (Vmax), and turnover number (kcat) were determined for pTS13 
dephosphorylation by PTPN1 and PTPN2 (Table 2.1) by fitting the initial rates of product 
formation to the Michaelis-Menten equation.  PTPN1 and PTPN2 showed first order kinetics 
with respect to pTS13 dephosphorylation.  Previous studies of peptide substrates for PTPN1 
have reported KM values of 2.6-23 μM, with kcat values of 55.7-78.9 s
-1
,
32-33
 comparable to 
the values observed for pTS13.  The kinetics of PTPN2 are less well documented, but a KM 
for phosphotyrosine was measured to be 300 μM,34 which is approximately 1000-fold higher 
than that seen for pTS13.  This is consistent with previous studies comparing PTP 
dephosphorylation for peptide substrates and phosphotyrosine alone.
33
  In summary, 
Michaelis-Menten kinetics measured with recombinant phosphatases and pTS13 are 
consistent with the existing literature, establishing the utility of this method for studying PTP 
activity in vitro. 
Inhibition of Recombinant Enzymes by Toxins From Diesel Exhaust.  Inhibitors 
of PTP activity were chosen to represent three major mechanisms of environmentally 
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relevant PTP inhibition: active site cysteine oxidation, covalent modification, and non-
oxidative inhibition by transition metals.
35
  Vanadium is a heavy metal found in fossil fuels 
and is released during combustion.
36
  Several oxidation states of vanadium are established 
PTP inhibitors, including pervanadate, which acts through direct oxidation of the catalytic 
cysteine.
37
  The polycyclic aromatic hydrocarbon 1,2-naphthoquinone is a naphthalene 
derivative generated by diesel combustion and petroleum processing which covalently and 
irreversibly arylates cysteine and histidine residues in the PTP active site.
7
  Finally, zinc is a 
major transition metal component of diesel exhaust particles that is theorized to inhibit PTP 
action by a non-redox mechanism involving direct interaction with vital active site residues.
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To establish whether PTP inhibition could be measured using our phosphatase 
activity reporter, pTS13 was incubated with recombinant PTPN1 and PTPN2 in the presence 
of the aforementioned inhibitors across a range of concentrations.  The enzyme was 
pretreated with sodium pervanadate, 1,2-naphthoquinone, or Zn
2+
, then pTS13 
dephosphorylation was assessed by CE.  Dose-response curves were generated (Figure 2.2) 
to establish this system as a useful method for measurement of PTP inhibition in vitro.  For 
PTPN1 inhibition, IC50 values for 1,2-naphthoquinone, pervanadate and Zn
2+
 were 
determined as 520 nM, 59 nM, and 28 μM respectively.  IC50 values for these compounds 
with PTPN2 were found to be 53 nM, 39 nM, and 87 μM.  These data are similar to previous 
reports of PTPN1 inhibition with 1,2-naphthoquinone (IC50: 1.6-5 μM),
7, 39
 pervanadate 
(IC50: 400 nM),
37
 and  PTPN2 inhibition with Zn
2+
 (85% inhibition at 100 μM).40  All three 
of these agents inhibit PTPs through complex and often overlapping mechanisms.  While 
Zn
2+
 is thought to bind directly to the PTP active site, it is also implicated in oxidative 
inhibition.  Pervanadate solutions exist as a mixture of vanadium oxidation states and contain 
40 
 
H2O2, itself an oxidative inhibitor of PTP activity.  Finally, 1,2-naphthoquinone irreversibly 
arylates the catalytic cysteine of PTPs, but also arylates other cysteine and histidine residues, 
which likely underlies the difference in inhibition between PTPN1 and PTPN2 for this agent.  
The complex mechanisms of inhibition exhibited by these environmental agents is also likely 
to be the basis for the variable shapes observed for dose-response curves generated for these 
PTP inhibitors. 
Lifetime of pTS13/TS13 in Cell Lysates.  To assess reporter susceptibility to 
intracellular degradation, TS13 was incubated with A431 cell lysates and samples were 
analyzed by CE.    One additional peak appeared over 3 hours.  This breakdown product was 
identified as the 8 residue fragment (6FAM-EELEDDYE-COOH) based on co-migration 
with the synthetic fragment.  The average rate of formation, and thus reporter breakdown, 
was 100 ± 8.2 fmol min
-1
 mg
-1
.  This rate is approximately 10
4
 times slower than the 
dephosphorylation rate measured in A431 lysates (discussed below), suggesting that TS13 is 
sufficiently robust to degradation for its intended applications.  Several peptides have been 
shown to undergo rapid degradation in cell lysates at rates ranging from 1.4-13 nmol min
-1
 
mg
-1
,
41-42
 approximately 10
4
-10
5
 fold faster than observed for TS13.  The peptidase resistance 
of TS13 is consistent with the finding that both glutamic and aspartic acid, the two most 
prevalent residues in this reporter, are moieties not preferred by peptidases.
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PTP activity and Inhibition in A431 Cell Lysates.  Unlike an isolated recombinant 
enzyme, cellular PTP activity is opposed by tyrosine kinases.  To determine if PTP activity 
could be measured in the context of cellular contents, pTS13 was incubated with whole cell 
lysates generated from A431 epidermoid carcinoma cells with and without the previously 
described environmental toxins (Figure 2.3).  In the absence of inhibitors, pTS13 
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dephosphorylation occurred at a rate of 1.4 ± 0.3 nmol min
-1
 mg
-1
.  Toxin inhibition of total 
PTP activity in A431 lysates was similar to that seen in recombinant PTPs, with IC50 values 
of 470 nM, 100 nM, and 35 μM for 1,2-naphthoquinone, pervanadate, and Zn2+ respectively. 
These values are comparable to those seen for recombinant PTPs, and agree with previously 
reported C6 cell lysate inhibition by Zn
2+
 (IC50: 31 μM).
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Lifetime of pTS13/TS13 in Single Cells.  The degradation resistance of the PTP 
reporter in living cells was tested by microinjection of single A431 cells with TS13 and 
single-cell analysis by CE.  A single degradation product was observed and corresponded to 
the 8 residue fragment based on migration relative to TS13.  This suggests that degradation 
patterns for TS13 in intact A431 cells and lysates are similar.  The degradation rate was 
linearly correlated (R
2
 = 0.8) with amount of TS13 injected, suggesting first-order kinetics.  
The amount of peptide delivered ranged from 0.2-35 amol and the median degradation rate 
was 39 fmol min
-1
 mg
-1
 with first and third quartiles (Q1 and Q3) of 22 and 440 fmol min
-1
 
mg
-1
, similar to the rate observed in A431 cell lysates.  The median half-life for TS13 was 35 
min (Q1 = 23 min, Q3 = 39 min), approximately 250-fold longer than a previous report for a 
native peptide in living cells.
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Single A431 Cell PTP Activity.  Cell lysates lack the organization and 
compartmentalization of the intact cell and  represent the pooled average of all processes 
occurring within a population, obscuring any intercellular heterogeneity.  To demonstrate the 
utility of pTS13 as a reporter of enzyme activity in single cells, individual A431 cells were 
analyzed with and without pretreatment with environmental toxins (Figure 2.4).  In untreated 
cells, a median of 0% (Q1 = 0%, Q3 = 11%) remaining phosphorylation was observed after 
60 s.  For the majority of these cells, 100% dephosphorylation had occurred within this time 
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frame, so rates could not be calculated. A lower limit to the rate was estimated by assuming a 
total protein concentration of 1 g/mL and a 500 fL cell volume
44
  for the average mammalian 
cell. The median rate was 2.1 pmol min
-1
 mg
-1
 (Q1 and Q3 of 1.1 and 8.0 pmol min
-1
 mg
-1
), 
significantly lower than seen in lysates, however this difference is overestimated by the 
inability to calculate exact rates for single cells, i.e. if 100% dephosphorylation is achieved in 
less than 60 s, actual rates will be higher than those calculated.  Compartmentalization of 
PTPs within the intact architecture of living cells could also contribute to lower 
dephosphorylation rates in single cells.  Plots of percent dephosphorylation vs. amount of 
peptide delivered showed that across the mass range observed (0.5-33 amol), PTP activity 
was not saturated.  Treatment of A431 cells with sodium pervanadate (1 mM) prior to 
microinjection resulted in a median of 53% (Q1 = 36%, Q3 = 77%) phosphorylation 
remaining in 60 s.  Results of 1,2-naphthoquinone (50 μM) and zinc pyrithione (100 μM) 
pretreatment were similar, yielding 41% (Q1 = 0%, Q3 = 96%) and 50% (Q1 = 46%, Q3 = 
74%) median phosphorylation remaining after 60 s, respectively.  Comparison of 
dephosphorylation for each treatment group versus untreated controls found statistically 
significant inhibition with p-values of 0.035, 0.0072, and 0.002 for 1,2-napthoquinone, zinc 
pyrithione, and pervanadate.  The measurement of the relative peak area of pTS13 to that of 
total peptide peak area in the presence of a lysed single cell was highly reproducible (RSD = 
0.018). Prior work has shown that the termination of intracellular reactions by laser lysis
45
 
and the introduction of cell contents into the capillary by electrokinetic injection
22
 are highly 
reproducible. Thus the most likely source of the measured variability in the PTP activity is 
the cellular heterogeneity in signaling. 
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The concentrations of 1,2-naphthoquinone and pervanadate necessary to ellicit 50% 
inhibition of PTP activity in single cells are 3 orders of magnitude higher than for lysates, 
while there is little difference seen for zinc pyrithione.  Although the ionophore pyrithione 
aids entry of Zn
2+
 into cells, pervanadate has no such ionophore or any established membrane 
transporter, potentially limiting its access to the cytoplasm. 1,2-naphthoquinone is highly 
lipophilic and may partition extensively in the cell membrane.  Additionally, unlike for Zn
2+
, 
inhibition of PTPs by pervanadate requires oxidation, and the antioxidative machinery of 
intact cells has not been diluted or disorganized as is the case in a lysate.  Exposure of intact 
cells to these toxins clearly inhibits PTP activity, and the variability between cells observed 
in these studies is consistent with previous reports of phenotypic heterogeneity in clonal 
populations,
46
 underlining the value of single-cell measurements as compared to bulk 
analysis of many cells.   
 
Conclusion 
 A novel chemical cytometry approach to measure PTP activity was demonstrated for 
analysis of recombinant enzymes in vitro, cell lysates, and single cells.  In each system, total 
PTP activity was assessed by measuring dephosphorylation of a fluorescent substrate peptide.  
Inhibition of PTP activity by environmental toxins was observed for recombinant enzymes 
and lysates at levels similar to those previously reported.  In single A431 cells, pretreatment 
with all toxins reduced PTP activity relative to untreated cells, with substantial variation 
between cells.  This heterogeneity seen in cultured cells illustrates the value of analyzing 
individual cells rather than population averages.  It should also be noted that relative to A431 
lysates, the inhibition of PTP activity in single A431 cells required much higher 
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concentrations of inhibitors.  The potential challenges to inhibitors, particularly pervanadate 
and 1,2-napthoquinone entering intact cells and therefore being less accessible to PTPs than 
would be the case in lysates has been discussed.  Additionally, intact cells possess highly 
effective mechanisms for limiting oxidative stress that are likely to be disrupted upon cell 
lysis.  Finally, as discussed in Chapter 1, PTP substrate recognition and activity depends on a 
complex network of interactions often involving protein-protein interactions in addition to 
the PTP itself.  Because an intact cell maintains its physiological architecture while cell lysis 
disrupts this natural organization, it is unsurprising that the PTP behavior of an intact cell 
would differ from that of a lysate. 
This approach provides several advantages over existing techniques.  The simplicity 
of sample preparation and assay protocols makes this technique an attractive option for 
analysis of recombinant enzymes and cell lysates, and the high sensitivity and flexibility is 
well suited to analysis of intact single cells.  This system does not require genetic 
manipulation of cells, making it useful for analysis of primary cells.  While microinjection 
was utilized in these studies to deliver reporter into intact cells, a variety of alternative 
delivery methods exist, including conjugation of cell penetrating peptides or lipids and 
liposome-based approaches.  Optimal reporter delivery conditions should afford efficient and 
reliable loading of intact cells while minimizing cellular stress response to avoid undue 
perturbation of signaling.  The ability to pre-select individual cells using microscopy permits 
analysis of desired subpopulations of viable cells in low viability or highly complex samples 
as well as very small samples.  These characteristics in particular suggest this technique will 
be valuable in the analysis of specimens such as airway brush biopsies and tumor samples.  
Additionally, enzyme activity is measured directly without the need for antibodies which, 
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combined with the analytical separation and tunability of a peptide substrate reporter, allows 
for simultaneous multiplexed measurements of several signaling events and provides a 
valuable complement to approaches focusing on genetics or protein expression.  While the 
specificity of pTS13 has not been investigated to date, characterizing which PTPs most 
efficiently dephosphorylate this reporter would provide more detail to the experimental 
readout and serve as a basis for potential structural refinements to tailor specificity to an 
intended target or group of targets.  In addition to refinement of the substrate sequence, the 
inclusion of targeting moieties such as nuclear localization signals or lipids could provide 
insight into PTP activity in the context of subcellular localization, an important aspect of PTP 
regulation.  In conclusion, the ability to analyze the effects of extracellular insults on 
signaling in small, heterogeneous samples of primary cells using a sensitive and flexible 
reporter promises to be a valuable new research tool in environmental health research in 
particular as well as the larger field of cell signaling. 
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Figure 2.1.  Separation of pTS13 (P) and TS13 (N) in 140 mM borate, 70 mM SDS, pH 7.4 
in a 50-μm diameter capillary (A) or with 140 mM borate, 150 mM SDS,  50 mM NaCl, pH 
7.4 in a 30-μm diameter capillary (B).  Reporter species were also separated from all 
fluorescent fragments (C), indicated by length in residues (e.g. fragment 1 is 6-FAM-Glu-
COOH), as well as from the 6-FAM internal standard (F). 
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Enzyme KM (nM) Vmax (nM s
-1
 ng
-1
) kcat (s
-1
) 
PTPN1 770 ± 250 2.2 ± 0.25 21 ± 2.4 
PTPN2 290 ± 54 3.1 ± 0.18 30 ± 1.7 
 
Table 2.1.  Kinetic constants KM and Vmax for pTS13 dephosphorylation by recombinant 
PTPN1 and PTPN2 were determined by fitting the Michaelis-Menten equation to initial 
reaction rates obtained over a range of substrate concentrations.  Kcat was calculated as 
Vmax/[E] where [E] is enzyme concentration. 
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Figure 2.2.  (A-C) Recombinant PTPN1 and (D-F) PTPN2 were pretreated with a range of 
inhibitor concentrations for 10 min and then incubated with pTS13 for 10 min.  Percent 
inhibition was calculated relative to the dephosphorylation observed in the absence of 
inhibitor.  Error bars represent the standard deviation of three replicates (n = 3). 
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Figure 2.3.  (A-C) A431 cell lysates (10 μg total protein) were pretreated with a range of 
inhibitor concentrations for 10 min and then incubated with pTS13 for 90 s.  Percent 
inhibition was calculated relative to the dephosphorylation observed in the absence of 
inhibitor.  Error bars represent the standard deviation of three replicates (n = 3). 
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Figure 2.4.  Single A431 cells were incubated in serum-free medium with and without 
inhibitors for 10 min, microinjected with pTS13, and analyzed by CE after 60 s incubation.  
Representative electropherograms of (A) full dephosphorylation in an untreated cell and (B) 
partial dephosphorylation in a pervanadate treated cell.  (C) Summary of PTP inhibition seen 
after treatment with (•) no inhibitor, (◦) 1 mM sodium pervanadate, (▼)100 μM zinc 
pyrithione , or (▽) 50 μM 1,2-naphthoquinone. Each marker represents a single cell while 
bars represent the mean for each group. 
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III.  Analysis of Protein Tyrosine Phosphatase Activity in Single Human Airway Cells 
ex vivo by Chemical Cytometry 
 
Overview 
 Protein tyrosine phosphatase (PTP) activity and inhibition in single human airway 
epithelial cells (hAECs) was measured using a capillary electrophoresis-based assay.  A 
fluorescent phosphopeptide PTP substrate was microinjected into single BEAS-2B 
immortalized bronchial epithelial cells and rapid dephosphorylation at a rate greater than 2.2 
pmol min
-1
 mg
-1
 was observed.  Pretreatment of the cells with the known PTP inhibitors 
pervanadate, Zn
2+
, and 1,2-naphthoquinone resulted in 76%, 69%, 100% median inhibition of 
PTP activity, respectively.  Reporter proteolysis in single BEAS-2B cells occurred at a 
median rate of 43 fmol min
-1
 mg
-1
 resulting in a median half-life of 20 min.  These studies 
were then extended to primary hAECs cultured from bronchial brushings of living human 
subjects. The reporter displayed a similar median half-life of 28 min in these single primary 
cells.  Dephosphorylation of the reporter occurred at rates greater than 2.2 pmol min
-1
 mg
-1
, 
and pre-incubation of the cells with the inhibitors pervanadate, Zn
2+
, and 1,2-naphthoquinone 
yielded 91%, 88%, and 87% median PTP inhibition, respectively.  Finally, single viable 
epithelial cells (n=3) were identified from a bronchial brushing specimen by positive 
immunostaining for the epithelial cell adhesion molecule (EpCAM) and absence of 
propidium iodide staining.  Dephosphorylation rates ranging from 0.35-36 pmol min
-1
 mg
-1
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were observed using capillary electrophoresis, demonstrating direct applicability of this 
technique for quantification of PTP activity in small, heterogeneous samples of primary cells. 
 
Introduction 
Cardiovascular disease is the leading cause of death in the US for both men and 
women, resulting in 25% of deaths in 2008.
1
  Inhalation of fine and ultrafine particulate 
matter (PM) generated by the combustion of diesel fuel is linked to increased blood 
pressure,
2
 decreased cardiac autonomic control,
3
 and significantly increased risk of heart 
attack and stroke.
4
  In vitro studies have demonstrated that inhaled PM leads to increased 
inflammatory signaling in airway cells
5-7
 and suggest that inhibition of protein tyrosine 
phosphatases (PTPs) plays a prominent role in this process.
8-9
  Immortalized airway cell lines 
and cultured primary airway epithelia are valuable model systems for these studies, but fail to 
fully recapitulate the phenotype of cells in the intact airway.
10
  Analysis of fresh airway 
epithelia, obtained through bronchial brushing, from human subjects exposed to well-
characterized PM would provide a more physiological context for studies of PM inhalation 
and its effects on airway signaling.  However, analysis of these ex vivo specimens is 
technically challenging due to the very small sample sizes (on average 10
5
 total cells) with 
cell viabilities of 11-33%. These samples are also composed of a mixed cell types with 
immune and squamous cells comprising 2-44% of the cells.
11
 
Previous analyses of epithelial cells from bronchial brushing specimens have utilized 
a variety of analytical methods although most studies have employed genetic approaches due 
to the readily available amplification methods for nucleotide analyses.  Fluorescence in situ 
hybridization (FISH)
12
 and polymerase chain reaction (PCR)
13
 have been used, respectively, 
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to detect chromosomal abnormalities and viral DNA in bronchial brushings.  RNA 
microarrays
14
 have been used to probe for transcriptional changes associated with airway 
disease.  Immunohistochemistry (IHC) using anti-phosphotyrosine antibodies has been 
employed to assess the presence of phosphoproteins in these samples as an indirect measure 
of PTP activity.
15
  However, none of these approaches directly measure PTP activity in living 
cells. 
Chemical cytometry, defined as the direct measurement of chemical processes at the 
single cell level, has the potential to be an important addition to techniques that characterize 
the genetic makeup and protein expression of bronchial brushing specimens.  Among the 
many chemical cytometry approaches that have been described,
16-17
 the use of capillary 
electrophoresis with laser-induced fluorescence (CE-LIF) is well-suited for addressing the 
challenges associated with bronchial brushings.  Limits of detection approaching 10
-21
 mol 
for CE-LIF
18
 permit the analysis of single cells and therefore size-limited samples.  This 
provides two additional advantages when dealing with heterogeneous samples.  Because 
information about each cell is acquired independently, variation between similar cells as well 
as between subpopulations is not lost due to population averaging.
16
  Additionally, individual 
cells of interest can be readily selected from a mixed population by vital staining to assess 
viability or extracellular markers.  Finally, using this approach enzyme activity can be 
measured directly without the need for genetic manipulation and is thus applicable to both 
immortalized and primary cells.
19
  The advantages of chemical cytometry in single-cell 
analyses led to the recent development of a single-cell assay of PTP activity
20
 using a 
fluorescent phosphopeptide PTP substrate termed “pTS13”.  Initial validation for this 
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approach was performed in A431 epidermoid carcinoma cells, a well-established model 
system for the study of tyrosine phosphorylation dynamics.
21
 
 In the present work, we demonstrate the utility of a previously described fluorescent 
peptide reporter for quantification of PTP activity in single human airway cells, including 
epithelial cells from a fresh bronchial brushing specimen.  Intracellular proteolysis of the 
peptide was assessed in single BEAS-2B cells using previously established capillary 
electrophoresis conditions capable of resolving the peptide from all fluorescent cleavage 
products.  PTP activity was then quantified in single BEAS-2B cells, as well as the inhibition 
of PTP activity resulting from exposure to three environmental toxins.  This approach was 
then extended to the analysis of single cultured primary human airway epithelial cells 
(hAECs), wherein reporter proteolysis, PTP activity, and PTP inhibition by toxins were 
quantified.  Finally, single viable epithelial cells in a fresh bronchial brushing specimen were 
identified and PTP activity was assessed, demonstrating the direct applicability of this 
chemical cytometry method to the analysis of fresh ex vivo airway samples.  Primary hAECs 
and bronchial brushings were obtained from Lisa A. Dailey and statistical analysis was 
performed by Eric Bair. 
 
Experimental Section 
Materials.  BEAS-2B cells were obtained from ATCC and primary human airway 
epithelial cells (hAECs) and bronchial brushing specimens were obtained from the Human 
Studies Division of the National Health and Environmental Effect Research Laboratory (US 
Environmental Protection Agency, Chapel Hill, NC).  Keratinocyte Basal Medium (KBM-
Gold), Bronchial Epithelial Basal Medium (BEGM), and Singlequots
TM
 growth factors, 
cytokines, and supplements were from Lonza.  Sylgard 184 polydimethylsiloxane (PDMS) 
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was purchased from Dow Corning, antibodies from Biolegend, and fluorescence microscopy 
filter sets from Chroma.  All other chemicals were purchased from either Sigma or Fisher. 
Cell Culture.  Wi-38 cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) plus 10% fetal bovine serum (FBS).  BEAS-2B cells were grown in Keritinocyte 
Growth Medium (KGM) prepared from KBM-Gold and a KGM-Gold Singlequots
TM
  kit.  
Primary hAECs were grown in Bronchial Epithelial Growth Medium (BEGM) prepared from 
BEBM and a BEGM Singlequots
TM
 kit.  BEAS-2B cultures were propagated in 25 cm
2
 tissue 
culture flasks and passaged when cells reached 60-80% confluency.  Cells intended for single 
cell analysis were grown on cell chambers comprising a silicone O-ring attached to a round 
no. 1 glass coverslip (25 mm diameter) with PDMS.  Cryopreserved hAECs (passage 3) were 
thawed and plated directly onto cell chambers.  Cells from the ex vivo bronchial brushing 
specimen were grown in cell chambers in which a polystyrene coverslip replaced the glass 
coverslip. 
Immunofluorescence.  Cells in a chamber were rinsed with 37 °C extracellular 
buffer (ECB; 10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, pH 
7.4) to remove media.  Excess ECB was aspirated and antibody solution (Alexafluor 647 
anti-human C326 (EpCAM) diluted 1:40 in ECB) was added to the chamber and incubated 
for 15 min at 37 °C.  Unbound antibody was then removed by rinsing the chamber with ECB.  
Propidium iodide solution (5 μg/mL in ECB) was then added to the chamber and cells were 
incubated for 5 min.  Excess propidium iodide was removed by rinsing with ECB and cells 
were imaged at 25X magnification.  Fluorescence images were obtained with xenon arc lamp 
illumination for detection of Alexafluor 647 (Cy5 filter set) and propidium iodide (Cy3 filter 
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set).  Digital images were acquired and processed using Micro-Manager and ImageJ 
software. 
Single cell capillary electrophoresis.  Single cells grown in chambers were 
microinjected with the PTP reporter, pTS13, or its non-phosphorylated analogue, TS13, 
using a Transjector 5246 microinjection system (Eppendorf AG, Hamburg, Germany).  Cells 
were kept at 37 °C under a flow of warm ECB until the desired time point was reached, 
whereupon the cell of interest was lysed with an Nd:YAG pulsed laser (532 nm).  Cell 
contents were aspirated into the capillary by electrokinetic injection (5 s at 79 V/cm) and CE-
LIF was performed at 263 V/cm on a customized system.  CE separations were performed in 
140 mM borate, 150 mM sodium dodecyl sulfate (SDS), 50 mM NaCl, pH 7.4.  Fluorescence 
and current data were collected using Labview (National Instruments, Austin, TX) and 
analyzed with Matlab (The Mathworks, Natick, MA) and Origin (OriginLab, Northampton, 
MA) software. 
Reporter lifetime measurement in single cells.  BEAS-2B or cultured hAECs were 
microinjected with TS13 and analyzed by CE-LIF after 1.5-12 min.  The amount of intact 
TS13 remaining was calculated as the corrected area of the TS13 peak by the sum of the 
corrected areas for all peaks.  Data was analyzed using Excel (Microsoft) and Origin.  
Single cell phosphatase activity assay.  BEAS-2B, cultured hAE, and fresh primary 
human airway cells were microinjected with pTS13 and analyzed by CE-LIF after 60 s.  For 
heterogeneous airway samples, epithelial cells were identified by anti-EpCAM vital staining 
prior to microinjection.  Dephosphorylation was assessed by dividing the corrected area of 
the pTS13 peak by the combined corrected areas of pTS13 and TS13 peaks.  Quantification 
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of TS13 and pTS13 was achieved by back-calculation from corrected peak area based on data 
from injection of known amounts of standard. 
Statistical analysis.  Comparisons of PTP inhibition for treated vs. control cells and 
across similarly treated cell lines was performed by bootstrapping as previously described.
20
   
 
Results and Discussion 
Lifetime of the PTP reporter in single BEAS-2B cells.  BEAS-2B cells are 
immortalized, non-tumorigenic human bronchial epithelial cells commonly used in airway 
research owing to their ability to recapitulate many of the features of normal primary airway 
cells including antioxidative capacity, inflammatory response, and matrix attachment.
22-24
  In 
order to accurately measure PTP activity in cells, the reporter must be robust to intracellular 
degradation.  To assess reporter susceptibility to intracellular degradation in BEAS-2B cells, 
single cells were microinjected with non-phosphorylated pTS13, termed “TS13”, and 
analyzed by CE-LIF.  The median amount of TS13 introduced into a single cell was 0.69 
amol (1 μM for a cell volume of 500 fL) with first and third quartiles (Q1 and Q3) of  0.21 
and 0.83 amol (0.42 and 2.0 μM). The electrophoretic traces possessed a peak co-migrating 
with TS13 and a peak co-migrating with the 8-residue fragment (6FAM-Glu-Glu-Leu-Glu-
Asp-Asp-Tyr-Glu-COOH) of TS13.  This peak is likely to be a degradation product of TS13, 
and was previously observed in A431 lysates and single cells.
20
  Average migration times for 
the TS13 and fragment peaks were 1220 ± 160 s and 1520 ± 260 s with efficiencies of  5.7 ± 
1.1 x 10
4
 and 6.6 ± 4.5 x 10
4
 theoretical plates and a resolution of 13 ± 4.9.  The area of the 
fragment peak relative to the combined area of all peaks was linearly correlated with 
incubation time (R
2
 = 0.76) (Figure 3.1A) and the degradation rate was linearly correlated 
with the amount of TS13 injected (R
2
 = 0.92) (Figure 3.1B), suggesting first-order reaction 
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kinetics.  Assuming an average protein concentration of 1 g/mL, the median rate of 
degradation was 43 fmol min
-1
 mg
-1
 (Q1 and Q3 of 15 and 82 fmol min
-1
 mg
-1
, equating to a 
median half-life of 20 min (Q1 and Q3 of 15 and 89 min).  This is comparable to the 39 fmol 
min
-1
 mg
-1
 median rate previously measured in single A431 cells.  Reporter degradation in 
BEAS-2B cells will result in 2-3% breakdown within the 60 s timespan of dephosphorylation 
experiments so reporter optimization to enhance proteolytic stability was unnecessary. 
Measurement of PTP activity in single BEAS-2B cells.  To determine the utility of 
pTS13 for measuring PTP activity in single human airway cells, BEAS-2B cells were 
microinjected and their contents analyzed by CE-LIF (Figure 3.2).  The median amount of 
reporter introduced into a cell was 1.1 amol (Q1 = 0.66 amol, Q3 = 3.0 amol).  Robust 
dephosphorylation was observed, with 90% (n = 10) of the cells completely 
dephosphorylating the peptide within 60s.  While exact rates could not be calculated for cells 
with no phosphorylation remaining, the median dephosphorylation rate was greater than 2.2 
pmol min
-1
 mg
-1
 (Q1 and Q3 of 1.1 and 6.0 pmol min
-1
 mg
-1
).  The single BEAS-2B cell that 
did not fully dephosphorylate the reporter contained 0.7 amol (1.4 μM) of reporter, within the 
interquartile range for amount loaded, suggesting that incomplete reporter dephosphorylation 
was not due to excessive loading, but more likely reflects intercellular heterogeneity.  
Reporter breakdown was negligible over the 60 s time course of these experiments.       
Inhibition of PTP activity in single BEAS-2B cells. Treatment of cells with 
environmental toxins resulted in substantial inhibition of PTP activity in single BEAS-2B 
cells.  Treatment with pervandate (1 mM), Zn
2+
 (100 μM), and 1,2-naphthoquinone (150 μM) 
resulted in statistically significant PTP inhibition relative to untreated cells (p < 0.0001), with 
medians of 76% (Q1 = 62%, Q3 = 86%), 69% (Q1 = 58%, Q3 = 73%), and 100% (Q1 = 95%, 
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Q3 = 100%) of the reporter remaining phosphorylated after 60 s.  As compared to A431 cells, 
pervanadate treatment of BEAS-2B cells resulted in greater PTP inhibition (p = 0.050) and 
intercellular heterogeneity, represented by the standard deviation of each sample, was less 
pronounced (p = 0.035).  Comparisons between BEAS-2B and A431 cells treated with Zn2
+
 
suggest greater inhibition among BEAS-2B cells, but lacked the statistical power to reach 
significance (p = 0.096).  Results of 1,2-naphthoquinone experiments are not directly 
comparable due to higher toxin concentrations used for BEAS-2B experiments than with 
A431 cells.  These data suggest that the PTPs are more susceptible to toxic inhibition in 
BEAS-2B cells than in A431, and that the clonal heterogeneity is less pronounced.  These 
conclusions are consistent with the relatively normal biochemical phenotype exhibited by 
BEAS-2B (discussed above) as well as established links between tumorigenic cell lines and 
increased heterogeneity.
25
 
Lifetime of the PTP reporter in single hAECs.  While the PTP reporter is robust to 
degradation in single BEAS-2B cells, breakdown in primary airway cells may differ.  
Therefore, the lifetime of the PTP reporter was evaluated in single primary airway epithelial 
cells by microinjection of TS13 and analysis by CE-LIF.  In addition to TS13, a second peak 
was observed with the same migration time as the 8-residue fragment peak seen in BEAS-2B 
cells.  The area of this fragment peak relative to the combined area of all peaks was linearly 
correlated with incubation time (R
2
 = 0.83) (Figure 3.3A).  The median amount of reporter 
injected into cells was 11 amol (22 μM) with Q1 and Q3 of 1.0 and 15 amol (2.0 and 30 μM), 
and a strong linear correlation was observed between the degradation rate and amount of 
TS13 loaded into a cell (R
2
 = 0.96) (Figure 3.3B), suggesting first-order degradation kinetics.  
The median degradation rate was 550 fmol min
-1
 mg
-1
 (Q1 and Q3 of 100 and 1700 fmol min
-
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1
 mg
-1
), equating to a median half-life of 28 min (Q1 and Q3 of 17 and 44 min) in cells.  
While the measured degradation rate in primary cells was an order of magnitude greater than 
seen in BEAS-2B cells, the average amount of peptide measured per cell was proportionately 
larger as well.  The mechanism underlying this disparity is unknown, but is likely due to 
differences in microinjection efficiency (i.e. differential delivery of reporter).  No difference 
was found between reporter half-life in primary hAECs and BEAS-2B (p = 0.28), supporting 
that the apparent rate disparity is a consequence of substrate concentration rather than innate 
differences in degradative capacity.  The similarity in reporter half-life and degradation 
pattern is consistent with the biochemical similarities between BEAS-2B and primary airway 
cells discussed earlier. 
Measurement of PTP activity in single primary hAECs.  Introduction of pTS13 
into living cells without the need for genetic manipulation allows direct analysis of primary 
cells.  To demonstrate the value of this technique for measuring PTP activity in primary cells, 
pTS13 was microinjected into single cultured primary hAECs and dephosphorylation was 
measured by CE-LIF (Figure 3.4).  Exact dephosphorylation rates for 7 of 12 hAECs could 
not be calculated due to complete dephosphorylation of pTS13 within the 60 s incubation 
time, but the median dephosphorylation rate was greater than 2.2 pmol min
-1
 mg
-1
 (Q1 and Q3 
of 0.20 and 18 pmol min
-1
 mg
-1
).  Plots of dephosphorylation rate vs total amount of reporter 
demonstrate that PTP activity was not saturated across the mass range of reporter delivered 
(0.1-100 amol), and that dephosphorylation rate is linearly correlated to amount of reporter 
(R
2
 = 0.99). 
Inhibition of PTP activity in single primary hAECs.  Treatment of cells with 
environmental toxins significantly inhibited PTP activity relative to untreated controls (p < 
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0.0001 for each treatment vs. control).  Cells treated with pervanadate, Zn2
+
, and 1,2-
naphthoquinone possessed a median of  91% (Q1 = 86%, Q3 = 98%), 88% (Q1 = 87%, Q3 = 
91%), and 87% (Q1 = 75%, Q3 = 92%) phosphorylation remaining after 60 s.  As compared 
to BEAS-2B cells, primary airway cells exhibited less inhibition by naphthoquinone (p = 
0.0027), but were more susceptible to inhibition by Zn
2+
 (p = 0.0039) and pervanadate (p = 
0.0001).  While the mechanism underlying these results is not well understood, they may 
imply a difference between BEAS-2B cells and primary airway cells with respect to 
antioxidative function, cation transport, or quinone metabolism.  Additionally, intercellular 
heterogeneity of response to treatment, measured as the standard deviation within a treatment 
group, was less pronounced in primary hAECs treated with pervanadate (p = 0.019 vs. 
BEAS-2B, p = 0.003 vs. A431) and Zn
2+
 (p = 0.0026 vs. BEAS-2B, p = 0.0161 vs. A431).  
Decreased heterogeneity in low passage number primary cells is consistent with the 
previously described development of heterogeneity in clonal populations.
25-26
 
Analysis of bronchial brushing specimen.  Bronchial brushings obtained from 
human subjects provide access to primary airway cells that have undergone exposure (e.g. to 
inhaled pollutants) in the most physiological environment possible.  However, analysis of 
these cells is challenging due to small sample size, low viability, and contamination with 
undesirable cells and mucus.  To demonstrate the applicability of pTS13 to the study of PTP 
activity in these ex vivo  samples, single viable epithelial cells from bronchial brushings were 
identified by vital staining (Figure 3.4A-C), microinjected with pTS13, and analyzed by CE-
LIF (Figure 3.4D-F).  The amount of pTS13 injected ranged from 1.2-41 amol (2.0-82 μM) 
and dephosphorylation rate was positively correlated with total amount of reporter (R
2
 = 
0.99).  Dephosphorylation rates ranged from 0.35-36 pmol min
-1
 mg
-1
, similar to the rates 
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observed in BEAS-2B and hAECs.  Analysis of 3 cells directly obtained from bronchial 
brushing of a human subject demonstrates the applicability of this technique to the 
measurement of PTP activity in ex vivo airway tissue samples. 
 
Conclusion 
 A recently developed chemical cytometry reporter of PTP activity was demonstrated 
to be a valuable tool for the study of human airway cells.  Immortalized bronchial epithelia, 
cultured primary airway epithelia, and unpassaged cells from an ex vivo human specimen 
were microinjected with a fluorescent phosphopeptide and dephosphorylation was quantified 
using CE-LIF.  Inhibition of PTP activity was observed in immortalized and primary cells 
after treatment with several environmental toxins.  Comparison of BEAS-2B and primary 
hAECs identified statistically significant differences in the response to these toxins, with 
hAECs showing greater response to both pervanadate and Zn
2+
, while BEAS-2B cells were 
more strongly inhibited by 1,2-naphthoquinone.  In addition to information about the 
magnitude of PTP activity and inhibition, analysis of cells individually provided insight into 
the heterogeneity within populations of BEAS-2B cells and hAECs.  Relative to BEAS-2B 
cells, the variability of response was smaller for hAECs treated with 1 mM pervanadate (p = 
0.019) or 100 μM Zn2+ (p = 0.0026).   Achieving statistical significance for comparisons of 
variability between populations is typically challenging, especially with small samples sizes, 
further demonstrating the power of this technique.  Finally, the pre-selection of viable 
epithelial cells for analysis was critical to the successful analysis of the heterogeneous, size-
limited ex vivo specimen.  While the sample size achieved in these experiments was 
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insufficient to draw biological conclusions, these analyses have demonstrated a unique new 
approach to studying PTP signaling in challenging primary samples. 
Signaling of PTPs is vitally important to cell physiology and the ability to measure 
PTP activity in ex vivo specimens will be a valuable tool for the study of conditions including 
cardiovascular and metabolic disease, immune dysfunction, and cancer.  It is increasingly 
clear that that no single approach is sufficient to decode the complexity of cell signaling, and 
direct enzyme activity measurement may be used to develop functional biomarkers of disease 
and pharmacodynamic readouts of exposure to toxins and therapeutics alike.   
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Figure 3.1.  Fragmentation of TS13 in single BEAS-2B cells.  Each symbol represents the 
measurement from a single cell. A) The percentage of the peak area of the fluorescent 8-
residue fragment with respect to the total peptide loaded into the cells was plotted over time.  
B) Rate of conversion of TS13 to the 8-residue fragment was plotted against the total amount 
of TS13 loaded into a cell. Dashed lines indicate linear regression with R
2
 = 0.76 (A) and 
0.92 (B).  
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Figure 3.2.  PTP activity in single BEAS-2B cells.  PTP activity was assessed in single 
BEAS-2B cells in the absence of toxins (◦) or after pretreatment with 1 mM pervanadate (•), 
100 μM Zn2+ (▽), or 150 μM 1,2-naphthoquinone (▼) for 10 min.  Dashes indicate mean 
phosphorylation remaining after 60 s. Each symbol marks the measurement from a single cell 
and the y-axis reflects the percentage of pTS13 relative to the total TS13 and pTS13. 
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Figure 3.3.  Fragmentation of TS13 in single hAECs.  Each symbol represents the 
measurement from a single cell. A) The percentage of the peak area of the fluorescent 8-
residue fragment with respect to the total peptide loaded into the cells was plotted over time.  
B) Rate of conversion of TS13 to the 8-residue fragment was plotted against the total amount 
of TS13 loaded into a cell. Dashed lines indicate linear regression with R
2
 = 0.83 (A) and 
0.96 (B). 
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Figure 3.4. PTP activity in single hAECs.  PTP activity was assessed in single hAECs in 
the absence of toxins (◦) or after pretreatment with 1 mM pervanadate (•), 100 μM Zn2+ (▽), 
or 150 μM 1,2-naphthoquinone (▼) for 10 min.  Dashes indicate mean phosphorylation 
remaining after 60 s. Each symbol marks the measurement from a single cell and the y-axis 
reflects the percentage of pTS13 relative to the total TS13 and pTS13. 
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Figure 3.5. Analysis of PTP activity in bronchial brushing specimens.  Viable epithelial 
cells from a bronchial brushing specimen were identified, microinjected with pTS13, and 
analyzed by CE-LIF.  After immunofluorescent staining, cells of interest were visualized 
using bright field (A) as well as fluorescence microscopy using Cy3 (B) and Cy5 (C) filter 
sets to assess viability and EpCAM expression.  Cells were then microinjected with a 6-
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FAM/pTS13 mixture and analyzed by CE-LIF after 60 s [electrophoretic traces shown in (D-
F)].  Labeled peaks represent 6-FAM (“F”), TS13 (“N”), and pTS13 (“P”).  Axes have been 
normalized to correct for migration time variability and signal intensity. 
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IV.  Conclusions and Future Directions 
 
 The protein tyrosine phosphatase (PTP) activity assay described in chapters 2 and 3 is 
a powerful new tool for the study of cell signaling.  By measuring enzyme activity in single 
cells directly through substrate dephosphorylation, this approach provides a number of 
benefits.  One important advantage of single-cell analysis is the preservation of data 
describing intercellular heterogeneity, information that is lost when analyzing bulk lysates.  
To date, this technique has provided the statistical power necessary to identify differences in 
intercellular heterogeneity in relatively small samples sizes (n ≤ 10).  Analysis of single cells 
also provides the opportunity to identify rare subpopulations of cells, the likelihood of which 
is related to the prevalence of that subpopulation within the sample.  For example, if a 
subpopulation represents 1% of the whole, the probability of identifying one cell from that 
subpopulation is 0.1 for n = 10, but 0.87 for n = 200.  As this technology matures, a focus on 
increased throughput will provide greater statistical power for describing population 
characteristics (e.g. central tendency, variance, shape of distribution) as well as for 
comparisons between populations.  This will also be especially valuable for studying subtle 
differences in signaling, such as characterizing response to low concentrations of toxins or 
drugs, or identifying differences between similar populations. 
An automated single-cell CE system has recently been developed, capable of 
analyzing 2.1 cells/min for 219 consecutive cells.
1
  This high-throughput system was used to 
measure sphingosine kinase activity by CE-LIF in single cells residing in microfabricated 
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wells.  To date, microinjection has not been integrated into this system, but automated 
microinjection systems with a throughput of 0.9 cells/min have been described.
2
    Higher 
throughput for single-cell CE may also be achievable through the adaptation and inclusion of 
capillary arrays.  Detection limits on the order of 10
-21
 mol for fluorescein and 10
-20
 for 
fluorescent sphingolipids have been reported for a parallel array of 32 capillaries performing 
CE simultaneously.
3
  High throughput microfluidic chemical cytometry (0.6 cells/min for an 
average of 50 single cells per experiment) has also been recently reported.
4
  In this system, 
electrophoretic separation of peptide reporter species, including breakdown products, takes 
place in a microfluidic channel rather than a capillary.  The integration of vital staining to 
identify cells of interest could allow focused analysis of large numbers of primary cells 
without the need for attachment to a substrate, though replacement of microinjection with an 
alternative reporter loading technique would also be necessary.  The integration of one or 
more of these approaches with the PTP activity reporter may substantially increase 
throughput. 
Another key advantage of this approach is the quantification of both substrate and 
product, which provides valuable information about PTP rates.  We have demonstrated that 
significant changes in dephosphorylation rate occur in A431, BEAS-2B, and primary airway 
cells in response to toxic inhibition.  The 500 fL average volume of a mammalian cell
5
 places 
inherent limitations on the amount of reporter than can be introduced into a single cell.  
Limits of detection on the order of 10-
21
 mol
6
 for capillary electrophoresis with laser-induced 
fluorescence detection (CE-LIF) are well suited to the quantification of analytes on the scale 
of the single cell.   An implication of this reporter mass limitation is that it establishes a finite 
time window after which the PTP reporter is completely dephosphorylated.  As reported in 
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chapters 2 and 3, when only one reporter species is detectable at the time of analysis, the 
exact rate of dephosphorylation cannot be calculated because the actual reaction time is 
unknown.  This phenomenon creates a statistical floor effect in which the true distribution of 
data is unknowable.  This effect is inconsequential for comparisons of clearly distinct 
populations, but reduces statistical power when dephosphorylation is very rapid in multiple 
populations. 
A potential avenue for increasing the temporal resolution of this technique, and thus 
its analytical power, is the development of a caged PTP substrate that can be 
dephosphorylated only after photolysis.  Caged phosphotyrosine has been synthesized and 
shown to uncage upon light exposure after inclusion in peptides using solid phase peptide 
synthesis.
7-9
  The ability to control the initiation of reporter dephosphorylation could permit 
considerably shorter time points.  A possible alternative method of addressing the floor effect 
resulting from rapid reporter dephosphorylation would be to use apply iterative peptide 
sequence modification, previously demonstrated to increase phosphorylation rates of kinase 
substrates,
10
 to create a sequence that is dephosphorylated more slowly, thereby increasing 
the time window available for observation of partial dephosphorylation. 
The tunability of peptide substrates combined with the high resolution, high peak 
capacity analytical separations afforded by CE-LIF provide great potential for future 
development of this approach to address increasingly complex biological questions.  CE 
provides the capacity to separate multiple analytes based on small differences in charge and 
hydrodynamic radius, and has been used to detect as many as 20 analytes simultaneously 
using single-color detection.
11
  This separation capacity combined with the capacity for 
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multi-color detection
12
 make possible the quantification of multiple enzyme activities in a 
single cell, leading to a better understanding of signaling networks and pathways. 
In conclusion, the PTP reporter described herein allows quantification of PTP activity 
as well as intercellular heterogeneity in a variety of cell populations, up to and including the 
small, heterogeneous populations of primary cells obtained from human subjects by 
bronchial brushing.  The combination of well-established methods such as solid phase 
peptide synthesis and capillary electrophoresis with leading-edge single-cell analysis 
technology provides a powerful and highly flexible tool for the study of PTP signaling at the 
single cell level.  This tool is directly applicable to the study of airway cells from human 
subjects, and has significant potential for future development. 
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